Phathom Drug Patent Portfolio
Phathom owns 3 orange book drugs protected by 2 US patents Given below is the list of Phathom's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9186411 | Pharmaceutical composition | 11 Aug, 2030 | Active |
| US7977488 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | 11 Aug, 2028 | Active |
Latest Legal Activities on Phathom's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Phathom.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 01 Mar, 2024 | US7977488 |
| Second letter to regulating agency to determine regulatory review period | 01 Mar, 2024 | US7977488 |
| Second letter to regulating agency to determine regulatory review period | 01 Mar, 2024 | US7977488 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US7977488 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US7977488 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US7977488 |
| Initial letter Re: PTE Application to regulating agency | 17 Aug, 2023 | US7977488 |
| Initial letter Re: PTE Application to regulating agency | 17 Aug, 2023 | US7977488 |
| Initial letter Re: PTE Application to regulating agency | 17 Aug, 2023 | US7977488 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 Jun, 2023 | US9186411 |
|
Email Notification
Critical
| 16 Jun, 2023 | US9186411 |
|
Email Notification
Critical
| 16 Jun, 2023 | US9186411 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 Jun, 2023 | US9186411 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 Jun, 2023 | US9186411 |
|
Email Notification
Critical
| 16 Jun, 2023 | US9186411 |
Phathom's Family Patents
Phathom Drug List
Given below is the complete list of Phathom's drugs and the patents protecting them.
1. Voquezna
Voquezna is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9186411 | Pharmaceutical composition |
11 Aug, 2030
(5 years from now)
| Active |
| US7977488 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
11 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Voquezna's drug page
2. Voquezna Dual Pak
Voquezna Dual Pak is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9186411 | Pharmaceutical composition |
11 Aug, 2030
(5 years from now)
| Active |
| US7977488 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
11 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Voquezna Dual Pak's drug page
3. Voquezna Triple Pak
Voquezna Triple Pak is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9186411 | Pharmaceutical composition |
11 Aug, 2030
(5 years from now)
| Active |
| US7977488 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
11 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Voquezna Triple Pak's drug page